What Makes Boston Scientific Corporation (BSX) an Investment Choice?

Core Insights - Polen Capital's "Polen Focus Growth Strategy" reported a gross return of 3.34% and a net return of 3.14% for Q3 2025, underperforming the Russell 1000 Growth Index at 10.51% and the S&P 500 Index at 8.12% [1] - The equity market's strong performance was attributed to enthusiasm for generative AI, strength in the semiconductor sector, positive economic surprises, fiscal policy optimism, and better-than-expected corporate earnings [1] Company Highlights - Boston Scientific Corporation (NYSE:BSX) was highlighted as a key stock, with a one-month return of -4.07% and a 52-week gain of 9.43%, closing at $94.95 per share with a market capitalization of $140.692 billion on October 13, 2025 [2] - Polen Capital acquired a 2% position in Boston Scientific, citing its leadership in medical products for cardiovascular conditions and significant growth driven by the Farapulse and Watchman platforms [3] - The Farapulse platform is noted for its innovative pulse field ablation (PFA) procedure, which is less invasive and more precise than traditional methods, while the Watchman segment is a leading product designed to reduce stroke risk in atrial fibrillation patients [3] - Boston Scientific is expected to achieve mid-teens earnings growth over the next 3-5 years, supported by low double-digit revenue growth and modest margin expansion [3]